SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-20-004819
Filing Date
2020-02-26
Accepted
2020-02-26 16:15:23
Documents
6
Period of Report
2020-02-26

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea119024-6k_enlivex.htm 6-K 25067
2 FORM OF SECURITIES PURCHASE AGREEMENT ea119024ex1-1_enlivex.htm EX-1.1 213716
3 FORM OF PLACEMENT AGENT WARRANT ea119024ex4-1_enlivex.htm EX-4.1 117149
4 OPINION OF YIGAL ARNON & CO. ea119024ex5-1_enlivex.htm EX-5.1 10835
5 OPINION OF GREENBERG TRAURIG, LLP ea119024ex5-2_enlivex.htm EX-5.2 20961
6 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON FEBRUARY 26, 2020 ea119024ex99-1_enlivex.htm EX-99.1 9541
  Complete submission text file 0001213900-20-004819.txt   398509
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 20655850
SIC: 2834 Pharmaceutical Preparations